Unlearn.AI

Digital

pharmaphorum podcast Episode 176a - Andrew Stelzer, Unlearn.AI

AI in drug development: The real hurdle is implementation

Web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about effectively implementing AI.

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks